Involvement of heparin binding protein midkine in vitreous of patients with proliferative diabetic retinopathy
Author: Sadık Altan Özal (Turkey)
Co-authors: Ece Özal
Purpose
This study aimed to evaluate whether midkine (MK) expression in the vitreous of proliferative diabetic retinopathy (PDR) patients and non-diabetic patients can play a role in pathogenesis.
Setting/Venue
Trakya University, School of Medicine, Edirne, Turkey
Methods
Patients who underwent surgery for epiretinal membrane and macular hole were considered as the first group (control group, n=20). Patients who were operated on for vitreous hemorrhage (VH) and tractional retinal detachment (TRD) secondary to PDR were considered as the second group (without aflibercept) (No preoperative anti-VEGF application: NPa-VEGF, n=15). The third group consisted, patients who were operated on for VH and TRD secondary to PDR, and who were injected with intravitreal aflibercept one week before the PPV surgery (with aflibercept) (Preoperative anti-VEGF application: Pa-VEGF, n=14). The concentration of MK, interleukin (IL) 6, and IL8 found in vitreous samples were determined by Enzyme-Linked Immunosorbent Assay (ELISA) using specific kits.
Results
The study included a total of 49 eyes of 49 patients undergoing PPV. The expression of IL-6 in vitreous samples of NPa-VEGF and Pa-VEGF was not significant (p> 0.05) compared to controls. Similar to IL-6, there was no difference in IL-8 concentrations between patient groups in vitreous samples (p> 0.05). The NPa-VEGF (p<0.007 vs control) and Pa-VEGF (p<0.046 vs control) groups had a significantly higher concentrations of MK in the vitreous fluid of the patients compared to the control group.
Conlusions
The findings of this study suggest that increased MK levels may play a role in PDR pathogenesis and may be used to prevent PDR or define new treatment strategies.
Financial Disclosure
No financial relationship with any of the commercial products or vendors in this presentation.